Mauro Comes Franchini1, Laura Cerchia2, Lisa Agnello3,4, Silvia Tortorella3,1, Annachiara d'Argenio3, Clarissa Carbone3, Simona Camorani3, Erica Locatelli1, Luigi Auletta5, Domenico Sorrentino6, Monica Fedele3, Antonella Zannetti5. 1. Department of Industrial Chemistry Toso Montanari, University of Bologna, Viale Risorgimento 4, 40136, Bologna, Italy. 2. Institute of Experimental Endocrinology and Oncology "Gaetano Salvatore", CNR, Via S. Pansini 5, 80131, Naples, Italy. cerchia@unina.it. 3. Institute of Experimental Endocrinology and Oncology "Gaetano Salvatore", CNR, Via S. Pansini 5, 80131, Naples, Italy. 4. University of Campania "L.Vanvitelli" Department of Precision Medicine, S. Andrea delle Dame - Via L. De Crecchio, 7 - 80138, Naples, Italy. 5. Institute of Biostructure and Bioimaging, CNR, Via T. De Amicis 95, 80145, Naples, Italy. 6. Ceinge-Biotecnologie Avanzate s.c.a.r.l, via Gaetano Salvatore 486, 80145, Naples, Italy.
Abstract
BACKGROUND: Management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is limited by scarce bioavailability, severe systemic side effects and drug resistance. Novel site-directed aptamer-based nanotherapeutics have the potential to overcome obstacles of chemotherapy. In this study we investigated the tumor targeting and the anti-tumorigenic effectiveness of novel cisplatin-loaded and aptamer-decorated nanosystems in TNBC. METHODS: Nanotechnological procedures were applied to entrap cisplatin at high efficacy into polymeric nanoparticles (PNPs) that were conjugated on their surface with the epidermal growth factor receptor (EGFR) selective and cell-internalizing CL4 aptamer to improve targeted therapy. Internalization into TNBC MDA-MB-231 and BT-549 cells of aptamer-decorated PNPs, loaded with BODIPY505-515, was monitored by confocal microscopy using EGFR-depleted cells as negative control. Tumor targeting and biodistribution was evaluated by fluorescence reflectance imaging upon intravenously injection of Cyanine7-labeled nanovectors in nude mice bearing subcutaneous MDA-MB-231 tumors. Cytotoxicity of cisplatin-loaded PNPs toward TNBC cells was evaluated by MTT assay and the antitumor effect was assessed by tumor growth experiments in vivo and ex vivo analyses. RESULTS: We demonstrate specific, high and rapid uptake into EGFR-positive TNBC cells of CL4-conjugated fluorescent PNPs which, when loaded with cisplatin, resulted considerably more cytotoxic than the free drug and nanovectors either unconjugated or conjugated with a scrambled aptamer. Importantly, animal studies showed that the CL4-equipped PNPs achieve significantly higher tumor targeting efficiency and enhanced therapeutic effects, without any signs of systemic toxicity, compared with free cisplatin and untargeted PNPs. CONCLUSIONS: Our study proposes novel and safe drug-loaded targeted nanosystems for EGFR-positive TNBC with excellent potential for the application in cancer diagnosis and therapy.
BACKGROUND: Management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is limited by scarce bioavailability, severe systemic side effects and drug resistance. Novel site-directed aptamer-based nanotherapeutics have the potential to overcome obstacles of chemotherapy. In this study we investigated the tumor targeting and the anti-tumorigenic effectiveness of novel cisplatin-loaded and aptamer-decorated nanosystems in TNBC. METHODS: Nanotechnological procedures were applied to entrap cisplatin at high efficacy into polymeric nanoparticles (PNPs) that were conjugated on their surface with the epidermal growth factor receptor (EGFR) selective and cell-internalizing CL4 aptamer to improve targeted therapy. Internalization into TNBC MDA-MB-231 and BT-549 cells of aptamer-decorated PNPs, loaded with BODIPY505-515, was monitored by confocal microscopy using EGFR-depleted cells as negative control. Tumor targeting and biodistribution was evaluated by fluorescence reflectance imaging upon intravenously injection of Cyanine7-labeled nanovectors in nude mice bearing subcutaneous MDA-MB-231 tumors. Cytotoxicity of cisplatin-loaded PNPs toward TNBC cells was evaluated by MTT assay and the antitumor effect was assessed by tumor growth experiments in vivo and ex vivo analyses. RESULTS: We demonstrate specific, high and rapid uptake into EGFR-positive TNBC cells of CL4-conjugated fluorescent PNPs which, when loaded with cisplatin, resulted considerably more cytotoxic than the free drug and nanovectors either unconjugated or conjugated with a scrambled aptamer. Importantly, animal studies showed that the CL4-equipped PNPs achieve significantly higher tumor targeting efficiency and enhanced therapeutic effects, without any signs of systemic toxicity, compared with free cisplatin and untargeted PNPs. CONCLUSIONS: Our study proposes novel and safe drug-loaded targeted nanosystems for EGFR-positive TNBC with excellent potential for the application in cancer diagnosis and therapy.
Authors: Neha Chopra; Holly Tovey; Alex Pearson; Ros Cutts; Christy Toms; Paula Proszek; Michael Hubank; Mitch Dowsett; Andrew Dodson; Frances Daley; Divya Kriplani; Heidi Gevensleben; Helen Ruth Davies; Andrea Degasperi; Rebecca Roylance; Stephen Chan; Andrew Tutt; Anthony Skene; Abigail Evans; Judith M Bliss; Serena Nik-Zainal; Nicholas C Turner Journal: Nat Commun Date: 2020-05-29 Impact factor: 14.919
Authors: Annachiara Sarnella; Ylenia Ferrara; Luigi Auletta; Sandra Albanese; Laura Cerchia; Vincenzo Alterio; Giuseppina De Simone; Claudiu T Supuran; Antonella Zannetti Journal: J Exp Clin Cancer Res Date: 2022-04-02
Authors: Md Rizwanullah; Mohammad Zaki Ahmad; Mohammed M Ghoneim; Sultan Alshehri; Syed Sarim Imam; Shadab Md; Nabil A Alhakamy; Keerti Jain; Javed Ahmad Journal: Pharmaceutics Date: 2021-11-29 Impact factor: 6.321